RG 6149

Drug Profile

RG 6149

Alternative Names: AMG 282; MSTT 1041 A; RG6149; RO 7187807; ST2 MAb

Latest Information Update: 08 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Genentech
  • Class Antiasthmatics; Bronchodilators; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 receptor-like 1 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma; Asthma
  • Preclinical Chronic obstructive pulmonary disease
  • No development reported Rhinosinusitis

Most Recent Events

  • 31 Jul 2018 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (SC) (NCT03615040)
  • 31 Jul 2018 Genentech plans the COPD-ST2OP phase II trial for Chronic obstructive pulmonary disease in United Kingdom (NCT03615040)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Allergic-asthma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top